Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02708407
Other study ID # IRAS project ID: 158992
Secondary ID ref: PG/13/27/29
Status Terminated
Phase N/A
First received
Last updated
Start date January 2016
Est. completion date June 2017

Study information

Verified date January 2020
Source University of Nottingham
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial is to establish whether ultrafiltration by peritoneal dialysis is a clinically effective treatment for patients with severe heart failure and moderate chronic kidney disease, thus improving quality of life and symptoms.


Description:

The trial is a multi-centre, prospective, randomised, unblended, controlled trial of intermittent PD with a single daily exchange of icodextrin plus best standard care versus best standard care for the treatment of severe HF and moderate CKD. A second exchange with glucose based solution may be given, should it be required in the investigator's/clinician's opinion. Investigators will randomise 130 participants for 32 weeks with randomisation stratified by participating centre. Participants will be recruited from specialist-led outpatient HF services in 6 NHS trusts and be managed by both cardiologists and nephrologists.

PD catheter insertion will occur according to the participating centre's institutional protocol. Treatment begins 1 week after catheter insertion and consists of a single nightly exchange.


Recruitment information / eligibility

Status Terminated
Enrollment 11
Est. completion date June 2017
Est. primary completion date June 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Severe heart failure (NYHA grade III or IV)

- Chronic kidney disease stage 3-4

- Fluid overload resistant to diuretics OR hospital admission for HF in last 6 months

- Left ventricular ejection fraction =40% in last 2 years (moderate/severe)

- Using optimal HF medication for = 4 weeks including ACE-inhibitor (angiotensin-converting-enzyme inhibitor) OR angiotensin receptor blocker AND aldosterone antagonist AND beta-blocker unless intolerant and without dose change for = 4 weeks

- Appropriately screened for revascularization and/or cardiac resynchronization therapy if clinically indicated.

Exclusion Criteria:

- Does not wish to participate

- Mental incapacity to consent

- CKD stage 5

- Normal renal excretory function

- Haemodynamically significant valvular disease amenable to surgery

- Cardiac or renal transplantation

- Considered by the investigator to unsuitable for PD due to previous abdominal surgeries, peritonitis, social circumstances or other reason

Study Design


Intervention

Procedure:
Peritoneal Dialysis
One week after insertion of a PD catheter the intervention group will received a single nightly exchange, using dialysis fluid containing icodextrin; a variable proportion of participants may require a second exchange as directed by the consultant nephrologist as part of routine care. The second exchange would use dialysis fluid containing glucose, not icodextrin. Support and training will be given to each participant by the PD specialist team.

Locations

Country Name City State
United Kingdom Derby Teaching Hospitals NHS Foundation Trust Derby Derbyshire

Sponsors (2)

Lead Sponsor Collaborator
University of Nottingham British Heart Foundation

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Episodes of PD associated peritoneal infection Recording the numbers of PD associated peritoneal infections Baseline to week 28
Other Adverse events spontaneously reported during the study Recording and reporting adverse events Baseline to week 28
Other Is the Derby Evaluation of Illness online visual analogue scale more sensitive than pen and ink questionnaires Comparison between the scores from pen and ink questionnaires and the online visual analogue scale Baseline to week 28
Primary The primary end-point is a change of 25 metres walked 6 Minute Walk Test Baseline to week 28
Secondary Change in KCCQ score Kansas City Cardiomyopathy Questionnaire Baseline to week 28
Secondary Change in SF36 score Short Form 36 questionnaire Baseline to week 28
Secondary Change in Derby Evaluation of Illness online visual analogue scale Derby Evaluation of Illness online visual analogue scale Baseline to week 28
Secondary Heart Failure related hospitalisations Recording the number of hospitalisations relating to Heart Failure Baseline to week 28
Secondary All cause hospitalisations Recording the number of hospitalisations for all causes Baseline to week 28
Secondary Heart failure related mortality Recording the number of heart failure deaths Baseline to week 28
Secondary All cause mortality Recording the number of all cause deaths Baseline to week 28
See also
  Status Clinical Trial Phase
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT05654272 - Development of CIRC Technologies
Active, not recruiting NCT05896904 - Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction N/A
Completed NCT05077293 - Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
Recruiting NCT05631275 - The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
Enrolling by invitation NCT05564572 - Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology N/A
Enrolling by invitation NCT05009706 - Self-care in Older Frail Persons With Heart Failure Intervention N/A
Recruiting NCT04177199 - What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
Terminated NCT03615469 - Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY) N/A
Recruiting NCT06340048 - Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure Phase 1/Phase 2
Recruiting NCT05679713 - Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
Completed NCT04254328 - The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure N/A
Completed NCT03549169 - Decision Making for the Management the Symptoms in Adults of Heart Failure N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05538611 - Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Completed NCT06026683 - Conduction System Stimulation to Avoid Left Ventricle Dysfunction N/A
Withdrawn NCT03091998 - Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support Phase 1
Recruiting NCT05564689 - Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy